Antisense oligonucleotides that target STAT3 mRNA have entered preclinical studies in patients with HNSCC and shown initial efficacy; however, rapid degradation of mRNA significantly limits its bioavailability (14). Here, STAT3 is linked to head and neck squamous cell carcinoma.